Question-and-Answer Session
Operator
(Operator instructions) We’ll first hear from Jonathan Aschoff of Brean Murray.
Jonathan Aschoff – Brean Murray
Good morning, Mike.
Michael Weiss
Hey, good morning, Jonathan.
Jonathan Aschoff – Brean Murray
I was wondering how sort of the fishing is going, the fishing for maybe something else to in license, what’s it like out there now looking around?
Michael Weiss
There is actually good opportunities. We are trying to be careful and thoughtful about what we might bring in. More obviously, we are seeing good things – we believe we are seeing good things from Zerenex and Perifosine, so we want to be careful about what we are looking at. I think the environment is reasonably friendly at this point for in-licensing opportunities and even small acquisition. So we are being careful. We are looking – we do see opportunities, but we haven’t made any commitments.
Jonathan Aschoff – Brean Murray
But it's something as active as it would have been, let’s say, six months ago or so, or maybe like four of five months ago.
Michael Weiss
Yes, our program is very active.
Jonathan Aschoff – Brean Murray
Okay. Thanks a lot, Mike.
Michael Weiss
Thanks, Jonathan.
Operator
Matt Kaplan, Ladenburg Thalmann.
Matt Kaplan – Ladenburg Thalmann
Hi. Good morning, Mike.
Michael Weiss
Hi, good morning.
Matt Kaplan – Ladenburg Thalmann
Just a quick question on Zerenex, with the changing in the enrollment, when do you now expect to have some data for the Phase II High-Dose Study?
Michael Weiss
Yes, our plan I think was always to finish the study by yearend. So that hasn’t changed and our fingers are crossed to be able to get that data out mostly by NKF, and that’s the major conference into the New Year. So we hope to be able to show it there for whatever therapy, the study is designed as a safety study. So, what we should expect is primarily safety information coming out of the study and I hope that we can get that out in someway into NKF.
Matt Kaplan – Ladenburg Thalmann
Will you announce some of the results before the, I guess, top line results before the NKF meeting?
Michael Weiss
Certainly, I don't think it is announce-able but certainly in a conference call, we would talk about if there is any safety issue or concern, we would clearly raise it. As a safety study, they are not really top line results that we can share. I will only [ph] to say that we didn’t see any safety concerns, and we felt comfortable that we can get to the higher doses. So, to get that as top line data in some respect, right, since the primary objective of the study is, can we get to the higher doses safely? So having said it now to myself out loud, I think it’s more than likely that at some point even before NKF that we would at least discuss whether it's on this kind of call or even a presentation that we didn’t have any issues. If we have any issue, we'll certainly raise it quickly.
- To read the full transcript on Seeking Alpha, click here »
